Yellow fever vaccine
暂无分享,去创建一个
A. Barrett | T. Monath | J. E. Staples | Thomas P. Monath | Mark D. Gershman | J. Erin Staples | Alan D.T. Barrett | M. Gershman
[1] D. Coulombier,et al. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast. , 2004, Vaccine.
[2] R. Kirk. An Epidemic of Yellow Fever In the Nuba Mountains, Anglo-Egyptian Sudan. , 1941 .
[3] S. Watowich,et al. Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. , 1999, Virology.
[4] Yi-Ling Lin,et al. Membrane Permeabilization by Small Hydrophobic Nonstructural Proteins of Japanese Encephalitis Virus , 1999, Journal of Virology.
[5] J. Kelso. Raw egg allergy-a potential issue in vaccine allergy. , 2000, The Journal of allergy and clinical immunology.
[6] T. Strine,et al. Multiple False Reactionse in Viral Antibody Screening Assays after Influenza Vaccination , 1995 .
[7] E. Konishi,et al. Ratios of subclinical to clinical Japanese encephalitis (JE) virus infections in vaccinated populations: evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations. , 2002, Vaccine.
[8] P. Desprès,et al. Determinants in the envelope E protein and viral RNA helicase NS3 that influence the induction of apoptosis in response to infection with dengue type 1 virus. , 2000, Virology.
[9] A. Rothman,et al. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. , 2002, Virology.
[10] John F Anderson,et al. Effect of Interferon-α2b Therapy on St. Louis Viral Meningoencephalitis: Clinical and Laboratory Results of a Pilot Study , 2004 .
[11] A. Allison,et al. Role of macrophages and antibody in resistance of mice against yellow fever virus. , 1971, Journal of immunology.
[12] H. Aragão. Report upon some researches on Yellow Fever , 2022 .
[13] J. Kruppenbacher,et al. Does the concurrent administration of an inactivated hepatitis A vaccine influence the immune response to other travelers vaccines? , 2006, Journal of travel medicine.
[14] S. M. de la Monte,et al. Immunoperoxidase detection of Yellow Fever virus after natural and experimental infections. , 1983, Tropical and geographical medicine.
[15] B. Miller,et al. Oral infection of Aedes aegypti with yellow fever virus: geographic variation and genetic considerations. , 1985, The American journal of tropical medicine and hygiene.
[16] F. Guirakhoo,et al. Molecular Basis for Attenuation of Neurovirulence of a Yellow Fever Virus/Japanese Encephalitis Virus Chimera Vaccine (ChimeriVax-JE) , 2001, Journal of Virology.
[17] S. Higgs,et al. Role of the yellow fever virus structural protein genes in viral dissemination from the Aedes aegypti mosquito midgut. , 2006, The Journal of general virology.
[18] R. Tesh,et al. Transovarial transmission of yellow fever virus by mosquitoes (Aedes aegypti). , 1979, The American journal of tropical medicine and hygiene.
[19] M. Burgess,et al. Age-related risk of adverse events following yellow fever vaccination in Australia. , 2004, Communicable diseases intelligence quarterly report.
[20] C. Peters,et al. Demonstration of yellow fever and dengue antigens in formalin-fixed paraffin-embedded human liver by immunohistochemical analysis. , 1991, The American journal of tropical medicine and hygiene.
[21] G. Tannock,et al. The development of an improved experimental yellow fever vaccine. , 1980, Journal of biological standardization.
[22] T. Monath. Stability of yellow fever vaccine. , 1996, Developments in biological standardization.
[23] J. Schlesinger,et al. Location of a neutralization determinant in the E protein of yellow fever virus (17D vaccine strain). , 1987, Virology.
[24] J. Roehrig,et al. New Mouse Model for Dengue Virus Vaccine Testing , 1999, Journal of Virology.
[25] T. Hase,et al. Flavivirus entry into cultured mosquito cells and human peripheral blood monocytes , 2005, Archives of Virology.
[26] J. Roehrig,et al. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein , 1992, Virology.
[27] M. Bouloy,et al. Nucleotide sequence comparison of the genome of two 17D-204 yellow fever vaccines. , 1989, Nucleic acids research.
[28] B. Okafor,et al. EPIDEMIC YELLOW FEVER IN EASTERN NIGERIA, 1986 , 1988, The Lancet.
[29] T. Monath,et al. Limitations of the complement-fixation test for distinguishing naturally acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areas. , 1980, The American journal of tropical medicine and hygiene.
[30] D. Vaughn,et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. , 2001, The American journal of tropical medicine and hygiene.
[31] A. Haddow. X.—The Natural History of Yellow Fever in Africa * , 1969 .
[32] M. Katz,et al. Failure of antibody production to yellow fever vaccine in children with kwashiorkor. , 1966, Tropical and geographical medicine.
[33] G. Halliday,et al. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. , 2000, The Journal of investigative dermatology.
[34] C. Scagnolari,et al. Neutralizing antibodies against endogenous interferon in myasthenia gravis patients. , 2004, European cytokine network.
[35] K. H. Williams,et al. Une épidémie de fièvre jaune au Sénégal en 1965: L'épidémie humaine , 1967 .
[36] M. Eibl,et al. Cellular and humoral immune responses in haemophiliacs after vaccination against tick‐borne encephalitis , 1992, British journal of haematology.
[37] J. Leduc,et al. Yellow Fever: A Decade of Reemergence , 1996 .
[38] C. Pournaras,et al. Multiple Evanescent White Dot Syndrome Following Simultaneous Hepatitis-A and Yellow Fever Vaccination , 2006, Ocular immunology and inflammation.
[39] T. Monath,et al. Yellow fever in the Gambia, 1978--1979: entomological aspects and epidemiological correlations. , 1980, The American journal of tropical medicine and hygiene.
[40] J. Dubuisson,et al. The Transmembrane Domains of the prM and E Proteins of Yellow Fever Virus Are Endoplasmic Reticulum Localization Signals , 2004, Journal of Virology.
[41] E. Mendelson,et al. Evaluation of ELISA-based sero-diagnosis of dengue fever in travelers. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[42] R. Lourenço-de-Oliveira,et al. Oral susceptibility to yellow fever virus of Aedes aegypti from Brazil. , 2002, Memorias do Instituto Oswaldo Cruz.
[43] L. Camacho,et al. Surveillance system of vaccine adverse events and local data analysis--the experience in a middle-sized city in Brazil, 1999-2001. , 2005, Vaccine.
[44] Anavaj Sakuntabhai,et al. A variant in the CD209 promoter is associated with severity of dengue disease , 2005, Nature Genetics.
[45] A. Sabin. Research on dengue during World War II. , 1952, The American journal of tropical medicine and hygiene.
[46] G. Chang,et al. An integrated target sequence and signal amplification assay, reverse transcriptase-PCR-enzyme-linked immunosorbent assay, to detect and characterize flaviviruses , 1994, Journal of clinical microbiology.
[47] R J Fletterick,et al. Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[48] E. Schiff,et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. , 1987, The New England journal of medicine.
[49] R. Cordellier. [The epidemiology of yellow fever in Western Africa]. , 1991, Bulletin of the World Health Organization.
[50] L. Camacho,et al. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial. , 2005, Revista de saude publica.
[51] M. Cetron,et al. The US-Certified Yellow Fever Vaccination Center Registry: a tool for travelers, state health departments, and vaccine providers. , 2006, Journal of travel medicine.
[52] S. Watowich,et al. Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. , 1998, Virology.
[53] G. Nybakken,et al. Antibodies against West Nile Virus Nonstructural Protein NS1 Prevent Lethal Infection through Fc γ Receptor-Dependent and -Independent Mechanisms , 2006, Journal of Virology.
[54] S. Higgs,et al. Characterization of an infectious clone of the wild-type yellow fever virus Asibi strain that is able to infect and disseminate in mosquitoes. , 2005, The Journal of general virology.
[55] G. Mootrey,et al. Anaphylaxis from yellow fever vaccine. , 1999, The Journal of allergy and clinical immunology.
[56] A. Barrett,et al. Phylogenetic and Evolutionary Relationships among Yellow Fever Virus Isolates in Africa , 2001, Journal of Virology.
[57] I. Levenbook,et al. The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination. , 1987, Journal of biological standardization.
[58] R. Schlesinger,et al. Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses. , 1956, Journal of immunology.
[59] W. Reed,et al. Experimental Yellow Fever , 2001 .
[60] A. Rizvanov,et al. Yellow fever virus strains Asibi and 17D-204 infect human umbilical cord endothelial cells and induce novel changes in gene expression. , 2005, Virology.
[61] T. Monath,et al. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. , 1981, Bulletin of the World Health Organization.
[62] Ren-Jye Lin,et al. Blocking of Interferon-Induced Jak-Stat Signaling by Japanese Encephalitis Virus NS5 through a Protein Tyrosine Phosphatase-Mediated Mechanism , 2006, Journal of Virology.
[63] K. Petry,et al. Postvaccinal inflammatory neuropathy: peripheral nerve biopsy in 3 cases , 2002, Journal of the peripheral nervous system : JPNS.
[64] G. Kuno,et al. Phylogeny of the Genus Flavivirus , 1998, Journal of Virology.
[65] R. Edelman,et al. Specific role of each human leukocyte type in viral infections. 3. 17D yellow fever virus replication and interferon production in homogeneous leukocyte cultures treated with phytohemagglutinin. , 1969, Journal of immunology.
[66] H. Zeller,et al. [Yellow fever epidemic in the extreme North of Cameroon in 1990: first yellow fever virus isolation in Cameroon]. , 1993, Bulletin of the World Health Organization.
[67] J. Muñoz-Jordán,et al. Inhibition of Alpha/Beta Interferon Signaling by the NS4B Protein of Flaviviruses , 2005, Journal of Virology.
[68] E. Gould,et al. Use of a monoclonal antibody specific for wild-type yellow fever virus to identify a wild-type antigenic variant in 17D vaccine pools. , 1989, The Journal of general virology.
[69] C. Mandl,et al. Attenuation of Tick-Borne Encephalitis Virus by Structure-Based Site-Specific Mutagenesis of a Putative Flavivirus Receptor Binding Site , 2000, Journal of Virology.
[70] F. Guirakhoo,et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. , 2002, Virology.
[71] R. S. Azevedo,et al. Yellow fever virus isolated from a fatal post vaccination event: an experimental comparative study with the 17DD vaccine strain in the Syrian hamster (Mesocricetus auratus). , 2004, Revista da Sociedade Brasileira de Medicina Tropical.
[72] M. Mallaret,et al. Evaluation du vaccin antiamaril thermostable de l'Institut Pasteur chez des voyageurs internationaux , 1986 .
[73] G. Girault,et al. Stability-related studies on 17D yellow fever vaccine. , 2000, Microbes and infection.
[74] R. Lanciotti. Molecular amplification assays for the detection of flaviviruses. , 2003, Advances in virus research.
[75] A. Rabello,et al. Low frequency of side effects following an incidental 25 times concentrated dose of yellow fever vaccine. , 2002, Revista da Sociedade Brasileira de Medicina Tropical.
[76] T. Monath,et al. Ontogeny of yellow fever 17D vaccine: RNA oligonucleotide fingerprint and monoclonal antibody analyses of vaccines produced world-wide. , 1983, The Journal of general virology.
[77] D. Gubler,et al. Dengue and dengue hemorrhagic fever : Its history and resurgence as a global public health problem , 1997 .
[78] P. Coursaget,et al. Simultaneous injection of plasma-derived or recombinant hepatitis B vaccines with yellow fever and killed polio vaccines. , 1995, Vaccine.
[79] J. Fox,et al. OBSERVATIONS ON THE OCCURRENCE OF ICTERUS IN BRAZIL FOLLOWING VACCINATION AGAINST YELLOW FEVER , 1942 .
[80] A. Barrett,et al. Attenuation of Japanese encephalitis virus by selection of its mouse brain membrane receptor preparation escape variants. , 1998, Virology.
[81] T. Monath,et al. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. , 2003, Advances in virus research.
[82] M. Cetron,et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. , 2001, Emerging infectious diseases.
[83] C. Parrish,et al. Broad cross-reactivity with marked fine specificity in the cytotoxic T cell response to flaviviruses. , 1992, The Journal of general virology.
[84] M. Lobigs,et al. Mechanism of Virulence Attenuation of Glycosaminoglycan-Binding Variants of Japanese Encephalitis Virus and Murray Valley Encephalitis Virus , 2002, Journal of Virology.
[85] M. Sangster,et al. Genetic control of host resistance to flavivirus infection in animals. , 1998, Revue scientifique et technique.
[86] E. De Clercq,et al. The Anti-Yellow Fever Virus Activity of Ribavirin Is Independent of Error-Prone Replication , 2006, Molecular Pharmacology.
[87] T. Monath,et al. Activity of Selected Amaryllidaceae Constituents and Related Synthetic Substances Against Medically Important RNA Viruses , 1992 .
[88] P. Marianneau,et al. Differing infection patterns of dengue and yellow fever viruses in a human hepatoma cell line. , 1998, Journal of Infectious Diseases.
[89] M. Niedrig,et al. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA , 1999, Tropical medicine & international health : TM & IH.
[90] D. Hatch,et al. Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998-2002. , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[91] M. F. L. E. Costa,et al. Efetividade da vacina antiamarílica 17D: uma avaliaçäo epidemiológica em serviços de saúde , 1997 .
[92] J. Fox,et al. FIELD STUDIES ON THE IMMUNE RESPONSE TO 17D YELLOW FEVER VIRUS RELATION TO VIRUS SUBSTRAIN, DOSE, AND ROUTE OF INOCULATION , 1943 .
[93] M. Crabtree,et al. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. , 2004, The American journal of tropical medicine and hygiene.
[94] R. Chanock,et al. Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys , 1996, Journal of virology.
[95] J. Fox,et al. BEHAVIOR OF 17D YELLOW FEVER VIRUS IN RHESUS MONKEYS RELATION TO SUBSTRAIN, DOSE, AND NEURAL OR EXTRANEURAL INOCULATION , 1943 .
[96] A. Barrett,et al. Genetic variation among strains of wild-type yellow fever virus from Senegal. , 1997, The Journal of general virology.
[97] W. A. Sawyer,et al. The Distribution of Yellow Fever Immunity in North America, Central America, the West Indies, Europe, Asia, and Australia, with Special Reference to the Specificity of the Protection Test. , 1937 .
[98] W. S. Gochenour,et al. SECTION OF BIOLOGICAL AND MEDICAL SCIENCES: EXPERIMENTAL YELLOW FEVER* , 1960 .
[99] F. Jousset,et al. [Isolation of the yellow fever virus in Paris from 2 imported human cases]. , 1979, Bulletin de la Societe de pathologie exotique et de ses filiales.
[100] M. Cetron,et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases , 2001, The Lancet.
[101] Eade Oe,et al. Coeliac lung disease. , 1978, Lancet.
[102] R. Andino,et al. Recombinant Yellow Fever Viruses Are Effective Therapeutic Vaccines for Treatment of Murine Experimental Solid Tumors and Pulmonary Metastases , 2000, Journal of Virology.
[103] D. Favre,et al. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. , 2005, The American journal of tropical medicine and hygiene.
[104] H. Schatzmayr,et al. Use of MAC-ELISA for evaluation of yellow fever vaccination. , 1992, Revista do Instituto de Medicina Tropical de Sao Paulo.
[105] Replication of yellow fever virus in the mouse central nervous system: comparison of neuroadapted and non-neuroadapted virus and partial sequence analysis of the neuroadapted strain. , 1996, The Journal of general virology.
[106] C. Wisseman,et al. Attenuated Living Type 1 Dengue Vaccines , 1963 .
[107] Dawei Liu,et al. [Adverse effects of attenuated yellow fever vaccine with multiple organ injury--a case report]. , 2005, Zhonghua yi xue za zhi.
[108] P. Desprès,et al. Dengue virus replication in human hepatoma cells activates NF-kappaB which in turn induces apoptotic cell death , 1997, Journal of virology.
[109] C. Draper. A yellow fever vaccine free from avian leucosis viruses , 1967, Epidemiology and Infection.
[110] J. Roehrig,et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. , 1994, The Journal of infectious diseases.
[111] S. Misbah,et al. What is Good’s syndrome? Immunological abnormalities in patients with thymoma , 2003, Journal of clinical pathology.
[112] T. Monath,et al. Genetic heterogeneity of yellow fever virus strains from Africa and the Americas. , 1986, The Journal of general virology.
[113] J. Quaresma,et al. Immunohistochemical examination of the role of Fas ligand and lymphocytes in the pathogenesis of human liver yellow fever. , 2006, Virus research.
[114] M. Guzmán,et al. Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[115] D. Clarke,et al. ANTIGENIC ANALYSIS OF CERTAIN GROUP B ARTHROPOD-BORNE VIRUSES BY ANTIBODY ABSORPTION , 1960, The Journal of experimental medicine.
[116] T. Monath,et al. Yellow fever vaccination and pregnancy: a four-year prospective study. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[117] W. A. Sawyer,et al. The yellow fever immunity survey of North, East and South Africa , 1936 .
[118] T. Monath,et al. Yellow fever in the Gambia, 1978--1979: epidemiologic aspects with observations on the occurrence of orungo virus infections. , 1980, The American journal of tropical medicine and hygiene.
[119] A. Segurado,et al. Severe yellow fever with 23-day survival. , 1988, Tropical and geographical medicine.
[120] Hester S. Tak,et al. Interindividual variation in the response by fibrinogen, C-reactive protein and interleukin-6 to yellow fever vaccination , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[121] A. Drouet,et al. Méningo-encéphalite après vaccination anti-amarile par la souche 17 D : deux observations , 1992 .
[122] R. Stjernholm,et al. Lymphocytes and yellow fever. I. Transient virus refractory state following vaccination of man with the 17-D strain. , 1970, Journal of immunology.
[123] T. Monath,et al. Geographic distribution and evolution of yellow fever viruses based on direct sequencing of genomic cDNA fragments. , 1994, The Journal of general virology.
[124] C. Mandl,et al. Mapping of Functional Elements in the Stem-Anchor Region of Tick-Borne Encephalitis Virus Envelope Protein E , 1999, Journal of Virology.
[125] A. Barrett,et al. Identification of envelope protein epitopes that are important in the attenuation process of wild-type yellow fever virus , 1992, Journal of virology.
[126] J. Fox,et al. Additional observations on the duration of humoral immunity following vaccination with the 17D strain of yellow fever virus. , 1948, American journal of hygiene.
[127] S. Gollins,et al. A new mechanism for the neutralization of enveloped viruses by antiviral antibody , 1986, Nature.
[128] W. A. Sawyer. Public Health Implications of Tropical and Imported Diseases : Yellow Fever and Typhus and the Possibility of Their Introduction into the United States. , 1944, American journal of public health and the nation's health.
[129] H. Penna,et al. PERSISTENCE OF YELLOW FEVER VIRUS IN THE BRAINS OF MONKEYS IMMUNIZED BY CEREBRAL INOCULATION. , 1943, Science.
[130] F. Guirakhoo,et al. High Fidelity of Yellow Fever Virus RNA Polymerase , 2004, Journal of Virology.
[131] S. Wiktor,et al. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. , 1997, The Pediatric infectious disease journal.
[132] G. Hartmann,et al. In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination. , 1998, The Journal of infectious diseases.
[133] A. Barrett,et al. Antibody-mediated early death in vivo after infection with yellow fever virus. , 1986, The Journal of general virology.
[134] E. Hindle,et al. A YELLOW FEVER VACCINE , 1928, British medical journal.
[135] C. Bryan,et al. Yellow fever in the Americas. , 2004, Bulletin of the Pan American Health Organization.
[136] A. T. D. Travassos da Rosa,et al. An epidemic of yellow fever in Central Brazil, 1972-1973. II. Ecological studies. , 1981, The American journal of tropical medicine and hygiene.
[137] C. Struchiner,et al. Risk assessment of yellow fever urbanization in Rio de Janeiro, Brazil. , 2004, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[138] P. Milburn,et al. Antiviral Cytotoxic T Cells Cross-Reactively Recognize Disparate Peptide Determinants from Related Viruses but Ignore More Similar Self- and Foreign Determinants , 2001, The Journal of Immunology.
[139] L. Whitman. Failure of Aëdes Aegypti to Transmit Yellow Fever Cultured Virus (17D)1 , 1939 .
[140] A. Barrett,et al. Mutation in NS5 protein attenuates mouse neurovirulence of yellow fever 17D vaccine virus. , 1998, The Journal of general virology.
[141] C. Rice,et al. Mutagenesis of the yellow fever virus NS2A/2B cleavage site: effects on proteolytic processing, viral replication, and evidence for alternative processing of the NS2A protein. , 1994, Virology.
[142] A. Barrett. Yellow fever vaccines. , 1997, Biologicals : journal of the International Association of Biological Standardization.
[143] R. Olsthoorn,et al. Sequence comparison and secondary structure analysis of the 3' noncoding region of flavivirus genomes reveals multiple pseudoknots. , 2001, RNA.
[144] L. Gayotto,et al. Histopathology of the human liver in yellow fever with special emphasis on the diagnostic role of the Councilman body , 1983, Histopathology.
[145] Robert T. Chen,et al. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002 , 2002 .
[146] J. H. Bauer. The Duration of Passive Immunity in Yellow Fever1 , 1931 .
[147] O. Klotz,et al. Jaundice and the Liver Lesions in West African Yellow Fever 1 , 1927 .
[148] Yellow Fever Vaccination, Avian Leukosis Virus, and Cancer Risk in Man , 1972, Science.
[149] R. Rico-Hesse,et al. Dengue Virus Structural Differences That Correlate with Pathogenesis , 1999, Journal of Virology.
[150] P. J. Wright,et al. The effects of site-directed mutagenesis on the dimerization and secretion of the NS1 protein specified by dengue virus. , 1993, Virology.
[151] A. Barrett,et al. Genetic Relationships and Evolution of Genotypes of Yellow Fever Virus and Other Members of the Yellow Fever Virus Group within the Flavivirus Genus Based on the 3′ Noncoding Region , 2004, Journal of Virology.
[152] C. Leake,et al. Isolations in a mosquito (Aedes pseudoscutellaris) cell line (Mos. 61) of yellow fever virus strains from original field material. , 1975, Intervirology.
[153] M. Hirsch,et al. Effects of Anti-thymocyte Serum on 17-D Yellow Fever Infection in Adult Mice , 1967, Nature.
[154] G. Chang,et al. Imported yellow fever in a United States citizen. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[155] Eva Harris,et al. Interferon-Dependent Immunity Is Essential for Resistance to Primary Dengue Virus Infection in Mice, Whereas T- and B-Cell-Dependent Immunity Are Less Critical , 2004, Journal of Virology.
[156] S Lopes Ode,et al. Studies on yellow fever vaccine. III--Dose response in volunteers. , 1988, Journal of biological standardization.
[157] A. Barrett,et al. Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. , 1997, Virology.
[158] J. X. Danauskas,et al. Heterotypic serologic responses after yellow fever vaccination; detection of persons with past St. Louis encephalitis or dengue. , 1967, Journal of immunology.
[159] T. Chambers,et al. Neuroadapted Yellow Fever Virus 17D: Genetic and Biological Characterization of a Highly Mouse-Neurovirulent Virus and Its Infectious Molecular Clone , 2001, Journal of Virology.
[160] E. Meltzer,et al. The safety of egg-containing vaccines for egg-allergic patients. , 1983, The Journal of allergy and clinical immunology.
[161] J. Schlesinger,et al. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. , 1986, The Journal of general virology.
[162] S. Kitchener. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. , 2004, Vaccine.
[163] B. Miller,et al. Detection of yellow fever viral RNA by nucleic acid hybridization and viral antigen by immunocytochemistry in fixed human liver. , 1989, The American journal of tropical medicine and hygiene.
[164] W. Bearcroft. The histopathology of the liver of yellow fever‐infected rhesus monkeys , 1957 .
[165] A. Heath,et al. Collaborative study to assess the suitability of a candidate International Standard for yellow fever vaccine. , 2004, Biologicals : journal of the International Association of Biological Standardization.
[166] J. Roehrig. Antigenic structure of flavivirus proteins. , 2003, Advances in virus research.
[167] M. Kron,et al. Threat of dengue haemorrhagic fever after yellow fever vaccination , 1997, The Lancet.
[168] J. Boshell,et al. Detección molecular del virus de la fiebre amarilla en muestras de suero de casos fatales humanos y en cerebros de ratón , 2003 .
[169] T. Monath,et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. , 2005, The American journal of tropical medicine and hygiene.
[170] S. Gollins,et al. Flavivirus infection enhancement in macrophages: an electron microscopic study of viral cellular entry. , 1985, The Journal of general virology.
[171] Fred Mitchell,et al. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. , 2005, The American journal of tropical medicine and hygiene.
[172] T. Monath,et al. Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein. , 1983, Virology.
[173] E. Holmes,et al. Population dynamics of flaviviruses revealed by molecular phylogenies. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[174] H. Laemmert. Susceptibility of Marmosets to Different Strains of Yellow Fever Virus. , 1944 .
[175] Joaquim Caetano de Almeida Netto,et al. ESTUDO DA COAGULAÇÃO SANGUÍNEA NA FEBRE AMARELA , 1973 .
[176] V. Alves,et al. Human fatal yellow fever. Immunohistochemical detection of viral antigens in the liver, kidney and heart. , 1992, Pathology, research and practice.
[177] P. Basanta,et al. Association of dengue hemorrhagic fever with the HLA system. , 1987, Haematologia.
[178] D. Fuchs,et al. Intra-nasal infection of macaques with Yellow Fever (YF) vaccine strain 17D: a novel and economical approach for YF vaccination in man. , 1999, Vaccine.
[179] M. Georges-Courbot,et al. Thermostability and efficacy in the field of a new, stabilized yellow fever virus vaccine. , 1985, Vaccine.
[180] S. Cryz,et al. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. , 1997, The Journal of infectious diseases.
[181] M. Diallo,et al. First evidence of natural vertical transmission of yellow fever virus in Aedes aegypti, its epidemic vector. , 1997, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[182] F. Macnamara,et al. Encephalitis following neurotropic yellow fever vaccine administered by scarification in Nigeria: epidemiological and laboratory studies. , 1955, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[183] B. Stoll,et al. Yellow fever vaccine and egg allergy. , 1995, Journal of Allergy and Clinical Immunology.
[184] G. Chang,et al. Nucleotide sequence variation of the envelope protein gene identifies two distinct genotypes of yellow fever virus , 1995, Journal of virology.
[185] Charles M. Rice,et al. Mutations in the Yellow Fever Virus Nonstructural Protein NS2A Selectively Block Production of Infectious Particles , 2002, Journal of Virology.
[186] J. Lang,et al. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. , 1999, The American journal of tropical medicine and hygiene.
[187] B. Henderson,et al. Immunologic studies with yellow fever and selected African group B arboviruses in rhesus and vervet monkeys. , 1970, The American journal of tropical medicine and hygiene.
[188] J. H. Bauer,et al. Experimental Transmission of Yellow Fever to Laboratory Animals. , 1928 .
[189] Monath Tp,et al. Does restricted distribution limit access and coverage of yellow fever vaccine in the United States , 1998 .
[190] J. H. Strauss,et al. Mutagenesis of the RGD motif in the yellow fever virus 17D envelope protein. , 1999, Virology.
[191] N. Karabatsos,et al. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. , 1989, The Journal of general virology.
[192] T. P. Hughes. A Precipitin Reaction in Yellow Fever , 1933, The Journal of Immunology.
[193] P. Hantson,et al. Analysis of two imported cases of yellow fever infection from Ivory Coast and The Gambia to Germany and Belgium. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[194] N. Scrimshaw,et al. Failure of yellow fever immunization to produce a catabolic response in individuals fully adapted to a protein-sparing modified fast. , 1977, The American journal of clinical nutrition.
[195] Y. Kobayashi,et al. Mutations in the envelope protein of Japanese encephalitis virus affect entry into cultured cells and virulence in mice. , 1992, Virology.
[196] E. Gould,et al. Reduction of yellow fever virus mouse neurovirulence by immunization with a bacterially synthesized non-structural protein (NS1) fragment. , 1988, The Journal of general virology.
[197] Robert T. Chen,et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. , 2005, Vaccine.
[198] Stanley M Lemon,et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[199] R. Galler,et al. Genetic variability among yellow fever virus 17D substrains. , 1998, Vaccine.
[200] W. Moss,et al. Immunization of children at risk of infection with human immunodeficiency virus. , 2003, Bulletin of the World Health Organization.
[201] V. Deubel,et al. Comparaison de différentes techniquespour la détection du virus de la fièvre jaune dans les prélèvements humains et les lots de moustiques: Intérêt d'une méthode rapide de diagnostic par ELISA , 1985 .
[202] H. Guzmán,et al. Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology. , 2001, The Journal of infectious diseases.
[203] M. Brinton,et al. Genetic resistance to flaviviruses. , 2003, Advances in virus research.
[204] H. H. Smith,et al. Yellow Fever Vaccination with Cultured Virus (17D) without Immune Serum 1 , 1938 .
[205] G. Low,et al. Observations on LABORATORY AND HOSPITAL INFECTIONS WITH YELLOW FEVER IN ENGLAND , 1931, British medical journal.
[206] H. Miller,et al. Multiple sclerosis and vaccination. , 1967, British medical journal.
[207] A. Barrett,et al. Yellow Fever Virus Infectivity for Bolivian Aedes aegypti Mosquitoes , 2004, Emerging infectious diseases.
[208] A. Barrett,et al. Phenotypic and molecular characterization of a non-lethal, hamster-viscerotropic strain of yellow fever virus. , 2005, Virus Research.
[209] J. P. Montgomery,et al. Possible West Nile virus transmission to an infant through breast-feeding--Michigan, 2002. , 2002, MMWR. Morbidity and mortality weekly report.
[210] C. B. Cropp,et al. Yellow fever monoclonal antibodies: type-specific and cross-reactive determinants identified by immunofluorescence. , 1984, The American journal of tropical medicine and hygiene.
[211] P. Lambin,et al. RESPONSE OF VOLTA CHILDREN TO JET INOCULATION OF COMBINED LIVE MEASLES, SMALLPOX AND YELLOW FEVER VACCINES. , 1964, Bulletin of the World Health Organization.
[212] G. Findlay,et al. The transmission of yellow fever virus to monkeys by mouth , 1939 .
[213] A. Barrett,et al. Molecular Characterization of a Hamster Viscerotropic Strain of Yellow Fever Virus , 2003, Journal of Virology.
[214] L. Phillips. The Epidemiology of Myasthenia Gravis , 2003, Neurologic clinics.
[215] T. Monath,et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases , 2001, The Lancet.
[216] M. J. Smith,et al. Mode of Action of Antirheumatic Drugs , 1971, British medical journal.
[217] S. Green,et al. A live, attenuated recombinant West Nile virus vaccine. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[218] B. Miller,et al. Partial nucleotide sequence of South American yellow fever virus strain 1899/81: structural proteins and NS1. , 1990, Journal of General Virology.
[219] J. S. Porterfield,et al. The flaviviruses (group B arboviruses): a cross-neutralization study. , 1974, The Journal of general virology.
[220] S. Gollins,et al. Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody on viral fate. , 1984, The Journal of general virology.
[221] M. Crowell,et al. CASE REPORT: Inflammatory Causes of Gastroparesis: Report of Five Cases , 2002, Digestive Diseases and Sciences.
[222] Mary E. Wilson,et al. Yellow fever immunizations: Indications and risks , 2004, Current infectious disease reports.
[223] Peter Nilsson,et al. DNA microarray technique for detection and identification of seven flaviviruses pathogenic for man , 2005, Journal of medical virology.
[224] M. Kortepeter,et al. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. , 2006, Vaccine.
[225] R. Shope,et al. Epidemiological aspects of the 1969 yellow fever epidemic in Nigeria. , 1972, Bulletin of the World Health Organization.
[226] B. Falgout,et al. Identification of Specific Nucleotide Sequences within the Conserved 3′-SL in the Dengue Type 2 Virus Genome Required for Replication , 1998, Journal of Virology.
[227] P. Hantson,et al. Corrélations anatomo-biologiques dans un cas de fièvre jaune importé de Gambie. , 2005 .
[228] H. Klenk,et al. Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants. , 2005, Virology.
[229] T. Monath,et al. Yellow fever and dengue—the interactions of virus, vector and host in the re-emergence of epidemic disease , 1994 .
[230] M. Yasuno,et al. Field studies on the gonotrophic cycle of Aedes aegypti in Bangkok, Thailand. , 1973, Journal of medical entomology.
[231] E. A. Beet. Yellow Fever Vaccination , 1955 .
[232] R. Doherty. Effects of yellow fever (17D) and West Nile viruses on the reactions of human appendix and conjunctive cells to several other viruses. , 1958, Virology.
[233] D. Simpson,et al. Yellow fever in Central Uganda, 1964 Part III. Virus isolation from man and laboratory studies , 1965 .
[234] E. Paoletti,et al. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. , 1992, Virology.
[235] E. De Clercq,et al. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. , 1996, Antiviral research.
[236] C. Rice,et al. Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence. , 1996, Virology.
[237] F. Guirakhoo,et al. Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine , 2001, Journal of Virology.
[238] A. Barrett,et al. The epidemiology of yellow fever in Africa. , 2002, Microbes and infection.
[239] N. Barrett,et al. Genome analysis and phylogenetic relationships between east, central and west African isolates of Yellow fever virus. , 2006, The Journal of general virology.
[240] P. Bonnel,et al. [Yellow fever in Africa during recent years]. , 1954, Bulletin of the World Health Organization.
[241] J. Bradshaw,et al. STABILITY AND INFECTIVITY OF AIRBORNE YELLOW FEVER AND RIFT VALLEY FEVER VIRUSES , 1963 .
[242] Ken Draper,et al. Single Mutation in the Flavivirus Envelope Protein Hinge Region Increases Neurovirulence for Mice and Monkeys but Decreases Viscerotropism for Monkeys: Relevance to Development and Safety Testing of Live, Attenuated Vaccines , 2002, Journal of Virology.
[243] Trowell Hc,et al. A fatal case of yellow fever in a European in Uganda. , 1953 .
[244] R. Sang,et al. Yellow Fever Outbreak, Southern Sudan, 2003 , 2004, Emerging infectious diseases.
[245] E. Amaral,et al. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. , 2006, Vaccine.
[246] K. Heeg,et al. Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine , 1985, Journal of medical virology.
[247] A. Tenório,et al. Yellow fever vaccine-associated viscerotropic disease and death in Spain. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[248] P. McMinn,et al. Molecular determinants of virulence: the structural and functional basis for flavivirus attenuation. , 2003, Advances in virus research.
[249] W. Popp,et al. Effects of yellow fever vaccination , 2001, The Lancet.
[250] Carol Beth Post,et al. Solution structure of dengue virus capsid protein reveals another fold. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[251] M. Rossmann,et al. Cryo-EM Reconstruction of Dengue Virus in Complex with the Carbohydrate Recognition Domain of DC-SIGN , 2006, Cell.
[252] H. Lakkis,et al. An open randomized study of inactivated hepatitis A vaccine administered concomitantly with typhoid fever and yellow fever vaccines. , 2006, Journal of travel medicine.
[253] S. Kitchen,et al. Yellow Fever accidentally Contracted in the Laboratory. A Study of Seven Cases. , 1931 .
[254] F. Guirakhoo,et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. , 2005, Biologicals : journal of the International Association of Biological Standardization.
[255] H. Tolou,et al. Homogeneity of Yellow Fever Virus Strains Isolated During an Epidemic and a Post-epidemic Period in West Africa , 2004, Virus Genes.
[256] M. Valade,et al. Une poussée épizootique de Fièvre jaune selvatique au Sénégal oriental. Isolement du virus de lots de Moustiques adultes mâles et femelles , 1979 .
[257] T. Monath,et al. Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria. , 1993, The American journal of tropical medicine and hygiene.
[258] M. Bras,et al. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[259] C. Rice,et al. Genetic analysis of the yellow fever virus NS1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation , 1997, Journal of virology.
[260] P. Marianneau,et al. Liver histopathology and biological correlates in five cases of fatal dengue fever in Vietnamese children , 2001, Virchows Archiv.
[261] Bali Pulendran,et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity , 2006, The Journal of experimental medicine.
[262] W. Rawlinson,et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine , 2001, The Lancet.
[263] F. Heinz,et al. Flavivirus structure and membrane fusion. , 2003, Advances in virus research.
[264] H. Guzmán,et al. Duration of infectivity and RNA of Venezuelan equine encephalitis, West Nile, and yellow fever viruses dried on filter paper and maintained at room temperature. , 2005, The American journal of tropical medicine and hygiene.
[265] O. Tomori. Impact of yellow fever on the developing world. , 1999, Advances in virus research.
[266] Cpt Gregg Gerasimon,et al. Rare Case of Fatal Yellow Fever Vaccine-associated Viscerotropic Disease , 2005, Southern medical journal.
[267] J. H. Strauss,et al. Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain. , 1993, Virology.
[268] W. Lloyd. The myocardium in yellow fever: II. The myocardial lesions in experimental yellow fever , 1931 .
[269] C. Howard,et al. Morphogenesis of yellow fever virus 17D in infected cell cultures. , 1988, The Journal of general virology.
[270] R. Pfeiffer,et al. Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies , 2003, International journal of cancer.
[271] F. Heinz,et al. Epitope mapping of flavivirus glycoproteins. , 1986, Advances in virus research.
[272] N. Karabatsos,et al. First recorded outbreak of yellow fever in Kenya, 1992-1993. I. Epidemiologic investigations. , 1998, The American journal of tropical medicine and hygiene.
[273] M. Sakaguchi,et al. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. , 1997, Vaccine.
[274] S. Higgs,et al. Manipulation of the yellow fever virus non-structural genes 2A and 4B and the 3'non-coding region to evaluate genetic determinants of viral dissemination from the Aedes aegypti midgut. , 2006, The American journal of tropical medicine and hygiene.
[275] R. Lourenço-de-Oliveira,et al. Aedes aegypti in Brazil: genetically differentiated populations with high susceptibility to dengue and yellow fever viruses. , 2004, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[276] E. Klein,et al. Characterization of blood mononuclear cells reacting with K 562 cells after yellow fever vaccination. , 1982, Cellular immunology.
[277] S. Sirinavin,et al. Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. , 1991, The American journal of tropical medicine and hygiene.
[278] Charles M. Rice,et al. Flaviviridae :T he Viruses and Their Replication , 2007 .
[279] D. Gubler,et al. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? , 2004, Comparative immunology, microbiology and infectious diseases.
[280] A. Barrett,et al. Amino acid substitution(s) in the stem-anchor region of langat virus envelope protein attenuates mouse neurovirulence. , 2001, Virology.
[281] M. Diamond,et al. Protective immune responses against West Nile virus are primed by distinct complement activation pathways , 2006, The Journal of experimental medicine.
[282] S. Kitchen,et al. VACCINATION AGAINST YELLOW FEVER WITH IMMUNE SERUM AND VIRUS FIXED FOR MICE , 1932, The Journal of experimental medicine.
[283] A. W. Sellards. The Behavior of the Virus of Yellow Fever in Monkeys and Mice. , 1931, Proceedings of the National Academy of Sciences of the United States of America.
[284] K. Miller,et al. Chloroquine does not adversely affect the antibody response to yellow fever vaccine. , 1986, The Journal of infectious diseases.
[285] A. Nisalak,et al. HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. , 2002, Tissue antigens.
[286] T. Oliphant,et al. Structural basis of West Nile virus neutralization by a therapeutic antibody , 2005, Nature.
[287] M. Receveur,et al. [Ketoacidotic coma 4 days after yellow fever vaccination]. , 1995, Presse medicale.
[288] A. Barrett,et al. Immunogenicity of wild-type and vaccine strains of Japanese encephalitis virus and the effect of haplotype restriction on murine immune responses. , 1993, Vaccine.
[289] D. J. Groves,et al. Examination of the envelope glycoprotein of yellow fever vaccine viruses with monoclonal antibodies. , 1989, Vaccine.
[290] Ying Zhang,et al. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus , 2003, Nature Structural Biology.
[291] A. Barrett,et al. Genetic Divergence and Dispersal of Yellow Fever Virus, Brazil , 2004, Emerging infectious diseases.
[292] M. Peltier. Yellow fever vaccination, simple or associated with vaccination against smallpox, of the populations of French West Africa by the method of the Pasteur Institute of Dakar. , 1947, American journal of public health and the nation's health.
[293] H. Fineberg,et al. Infections in HIV-infected travelers: risks and prevention. , 1991, Annals of Internal Medicine.
[294] E. Afari,et al. Antibody response to 17D yellow fever vaccine in Ghanaian infants. , 2001, Bulletin of the World Health Organization.
[295] J. Leduc,et al. Transovarial transmission of yellow fever virus by a sylvatic vector, Haemagogus equinus. , 1981, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[296] A. Rothman,et al. Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus , 1996, Journal of virology.
[297] K. Mullane,et al. Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002. , 2002, MMWR. Morbidity and mortality weekly report.
[298] J. Fox,et al. The cultivation of yellow fever virus; observations on the infection of developing chick embryos. , 1947, American journal of hygiene.
[299] R C Weir,et al. Host cell selection of Murray Valley encephalitis virus variants altered at an RGD sequence in the envelope protein and in mouse virulence. , 1990, Virology.
[300] T. Tsai,et al. Congenital yellow fever virus infection after immunization in pregnancy. , 1993, The Journal of infectious diseases.
[301] H. W. Burruss,et al. Aqueous-Base Yellow Fever Vaccine , 1943 .
[302] J. Huggins. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. , 1989, Reviews of infectious diseases.
[303] S. de A Nishioka,et al. Yellow fever vaccination during pregnancy and spontaneous abortion: a case‐control study , 1998, Tropical medicine & international health : TM & IH.
[304] I. Tokimatsu,et al. Genetic Determinants Responsible for Acquisition of Dengue Type 2 Virus Mouse Neurovirulence , 1998, Journal of Virology.
[305] E. Holmes,et al. Secondary structure of the 3'-untranslated region of yellow fever virus: implications for virulence, attenuation and vaccine development. , 1997, The Journal of general virology.
[306] G. Findlay. Immunization against Yellow Fever. , 1934 .
[307] T. Chambers,et al. Yellow Fever Virus Encephalitis: Properties of the Brain-Associated T-Cell Response during Virus Clearance in Normal and Gamma Interferon-Deficient Mice and Requirement for CD4+ Lymphocytes , 2001, Journal of Virology.
[308] J. Lang,et al. Host-cell interaction of attenuated and wild-type strains of yellow fever virus can be differentiated at early stages of hepatocyte infection. , 2006, Microbes and infection.
[309] F. Laurencet,et al. Effects of yellow fever vaccination , 2001, The Lancet.
[310] T. Belt,et al. The Pathology of the Liver in Yellow Fiver. , 1930, The American journal of pathology.
[311] R. Steinman,et al. DC-SIGN (CD209) Mediates Dengue Virus Infection of Human Dendritic Cells , 2003, The Journal of experimental medicine.
[312] D. Wilson,et al. Clinical features of yellow fever cases at Vom Christian Hospital during the 1969 epidemic on the Jos Plateau, Nigeria. , 1972, Bulletin of the World Health Organization.
[313] C. Dommann,et al. Encephalitis in a 13-year-old boy following 17D yellow fever vaccine. , 1990, The Journal of infection.
[314] R. Gibbs,et al. Single nucleotide polymorphisms in genes for 2'-5'-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. , 2005, The Journal of infectious diseases.
[315] Michael S. Diamond,et al. Modulation of Dengue Virus Infection in Human Cells by Alpha, Beta, and Gamma Interferons , 2000, Journal of Virology.
[316] S. Green,et al. Yellow fever vaccine: a successful vaccination of an immunocompromised patient , 2004, European journal of haematology.
[317] M. T. Ashcroft. Historical evidence of resistance to yellow fever acquired by residence in India. , 1979, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[318] C. Wisseman,et al. Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. , 1963, The American journal of tropical medicine and hygiene.
[319] M. Guzmán,et al. MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination. , 2003, Journal of virological methods.
[320] I. Kurane,et al. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. , 2005, Vaccine.
[321] M. Sakaguchi,et al. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. , 1996, The Journal of allergy and clinical immunology.
[322] R. Eidex. History of thymoma and yellow fever vaccination , 2004, The Lancet.
[323] A. Barrett,et al. The French neurotropic vaccine strain of yellow fever virus accumulates mutations slowly during passage in cell culture. , 2000, Virus research.
[324] S. Punyagupta,et al. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. , 2002, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[325] J. Hadler,et al. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. , 1993, JAMA.
[326] H. Sampson,et al. Safe administration of influenza vaccine to patients with egg allergy. , 1998, The Journal of pediatrics.
[327] R. Marchevsky,et al. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys. , 2003, Virology.
[328] Eduardo Massad,et al. Dengue and the risk of urban yellow fever reintroduction in São Paulo State, Brazil. , 2003, Revista de saude publica.
[329] J. Stephenson,et al. Variation in the biological function of envelope protein epitopes of yellow fever vaccine viruses detected with monoclonal antibodies. , 1992, Biologicals : journal of the International Association of Biological Standardization.
[330] H. Schatzmayr,et al. Isolation and characterization of wild type yellow fever virus in cases temporally associated with 17DD vaccination during an outbreak of yellow fever in Brazil. , 2004, Vaccine.
[331] M. Cornet,et al. [The 1983 yellow fever epidemic in Burkina Faso]. , 1986, Bulletin of the World Health Organization.
[332] J. Digoutte,et al. A propos de trois cas de fièvre jaune contractée au Sénégal. , 1981 .
[333] J. Lang,et al. Safety and immunogenicity of a new inactivated hepatitis A vaccine in concurrent administration with a typhoid fever vaccine or a typhoid fever + yellow fever vaccine. , 1997, Advances in Therapy.
[334] K. Starling,et al. Immunologic chimerism as evidence of bone marrow graft acceptance in an identical twin with acute lymphocytic leukemia. , 1975, Experimental hematology.
[335] Michael Engle,et al. A Critical Role for Induced IgM in the Protection against West Nile Virus Infection , 2003, The Journal of experimental medicine.
[336] J. Hughes,et al. Measures against yellow fever entry into the United States. , 1958, Public health reports.
[337] Á. L. Bertho,et al. Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus. , 2005, Memorias do Instituto Oswaldo Cruz.
[338] F. Guirakhoo,et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. , 2001, Virology.
[339] Matthias Niedrig,et al. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: A model of human flavivirus infection , 1998, Journal of medical virology.
[340] K. Gyr,et al. Simultaneous vaccination against cholera and yellow fever. , 1973, Lancet.
[341] M. Theiler,et al. Modification of the virulence of yellow fever virus by cultivation in tissues in vitro , 1936 .
[342] P. Brés. Benefit versus risk factors in immunization against yellow fever. , 1979, Developments in biological standardization.
[343] Pedro Fernando da Costa Vasconcelos. Febre amarela Yellow fever , 2003 .
[344] E Massad,et al. The risk of yellow fever in a dengue-infested area. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[345] V. Deubel,et al. Introduction à l'analyse de la virulence du virus de la fièvre jaune (Flaviviridae): études génétiques, immunochimiques et biologiques comparatives entre les souches atténuées vaccinales et leurs souches parentales , 1986 .
[346] J. Quaresma,et al. Revisiting the liver in human yellow fever : Virus-induced apoptosis in hepatocytes associated with TGF-β, TNF-α and NK cells activity , 2006 .
[347] Eduardo Massad,et al. Yellow fever vaccination: how much is enough? , 2005, Vaccine.
[348] H. Guzmán,et al. Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease. , 2004, The American journal of tropical medicine and hygiene.
[349] Y. Modis,et al. A ligand-binding pocket in the dengue virus envelope glycoprotein , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[350] M. Cetron,et al. Prevention of yellow fever in persons traveling to the tropics. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[351] C. Michelet,et al. Yellow fever vaccine is safe and effective in HIV-infected patients , 2004, AIDS.
[352] Donald J. Sharp,et al. Fatal yellow fever in a traveler returning from Amazonas, Brazil, 2002. , 2002, JAMA.
[353] F. Guirakhoo,et al. New developments in flavivirus vaccines with special attention to yellow fever , 2005, Current opinion in infectious diseases.
[354] M. Cetron,et al. Yellow Fever 17D Vaccine Safety and Immunogenicity in the Elderly , 2005, Human vaccines.
[355] J. Schlesinger,et al. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. , 1993, Virology.
[356] R. Tesh,et al. Transovarial transmission of yellow fever virus in Stegomyia mosquitoes. , 1980, The American journal of tropical medicine and hygiene.
[357] W. Bancroft,et al. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status. , 1983, The Journal of infectious diseases.
[358] A. Fagbami,et al. Yellow fever haemagglutination-inhibiting, neutralising and IgM antibodies in vaccinated and unvaccinated residents of Ibadan, Nigeria. , 1990, Comparative immunology, microbiology and infectious diseases.
[359] C. Rice,et al. Molecular biology of the flaviviruses. , 1987, Microbiological sciences.
[360] Antonio Lanzavecchia,et al. Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming , 2004, Nature Immunology.
[361] M. Brinton,et al. Translation elongation factor-1 alpha interacts with the 3' stem-loop region of West Nile virus genomic RNA , 1997, Journal of virology.
[362] G. Findlay,et al. Hepatitis and Jaundice Associated with Immunization against Certain Virus Diseases , 1938, Proceedings of the Royal Society of Medicine.
[363] M. Theiler,et al. The relative resistance of dengue-immune monkeys to yellow fever virus. , 1975, The American journal of tropical medicine and hygiene.
[364] V. Barban,et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. , 2007, Vaccine.
[365] I M Longini,et al. Determinants and predictors of dengue infection in Mexico. , 1991, American journal of epidemiology.
[366] B. Reisberg,et al. The Original Haernorrhagic Fever: Yellow Fever , 1969, British journal of haematology.
[367] M. Crabtree,et al. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. , 2000, The American journal of tropical medicine and hygiene.
[368] F. Liprandi. Isolation of plaque variants differing in virulence from the 17D strain of yellow fever virus. , 1981, The Journal of general virology.
[369] C. B. Cropp,et al. Indirect fluorescent antibody test for the diagnosis of yellow fever. , 1981, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[370] P. McMinn,et al. Attenuation of Murray Valley Encephalitis Virus by Site-Directed Mutagenesis of the Hinge and Putative Receptor-Binding Regions of the Envelope Protein , 2001, Journal of Virology.
[371] F. Ennis,et al. Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones , 1996, Journal of virology.
[372] A. T. D. Travassos da Rosa,et al. Jungle yellow fever: clinical and laboratorial studies emphasizing viremia on a human case. , 1995, Revista do Instituto de Medicina Tropical de Sao Paulo.
[373] P. Shi,et al. Serologic diagnosis of West Nile virus infection , 2003, Expert review of molecular diagnostics.
[374] E. Harris,et al. Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. , 2004, Virology.
[375] C. Rice,et al. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. , 1995, Virus research.
[376] Hugh H. Smith,et al. THE ADAPTATION OF UNMODIFIED STRAINS OF YELLOW FEVER VIRUS TO CULTIVATION IN VITRO , 1937, The Journal of experimental medicine.
[377] F. Jousset,et al. [Study of the vertical transmission and horizontal transmission of "Drosophila melanogaster" and "Drosophila immigrans" picornavirus (author's transl)]. , 1975, Annales de microbiologie.
[378] J. Schlesinger,et al. Growth of 17D yellow fever virus in a macrophage-like cell line, U937: role of Fc and viral receptors in antibody-mediated infection. , 1981, Journal of immunology.
[379] J. Casals,et al. The serological reactions in yellow fever. , 1958, The American journal of tropical medicine and hygiene.
[380] J. Roche,et al. Comparative clinical study of a new 17D thermostable yellow fever vaccine. , 1986, Vaccine.
[381] I. Potasman,et al. Late vaccination against yellow fever of travelers visiting endemic countries. , 2006, Travel medicine and infectious disease.
[382] V. Vorndam,et al. Urbanisation of yellow fever in Santa Cr uz, Bolivia , 1999, The Lancet.
[383] E. G. Westaway,et al. trans-Complementation Analysis of the Flavivirus Kunjin ns5 Gene Reveals an Essential Role for Translation of Its N-Terminal Half in RNA Replication , 1999, Journal of Virology.
[384] J. Fox,et al. THE DURATION OF IMMUNITY FOLLOWING VACCINATION WITH THE 17D STRAIN OF YELLOW FEVER VIRUS , 1943 .
[385] W. A. Sawyer,et al. THE USE OF MICE IN TESTS OF IMMUNITY AGAINST YELLOW FEVER , 1931, The Journal of experimental medicine.
[386] W. A. Sawyer. The Persistence of Yellow Fever Immunity. , 1931 .
[387] D. Adkins,et al. Biological characterization of plaque-size variants of yellow fever virus in mosquitoes and mice. , 1988, Acta virologica.
[388] J. H. Strauss,et al. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[389] De-shan Zhou,et al. Neutralizing mechanism of a monoclonal antibody against Japanese encephalitis virus glycoprotein E. , 1998, The American journal of tropical medicine and hygiene.
[390] Internal proteolysis of the NS3 protein specified by dengue virus 2. , 1997, The Journal of general virology.
[391] D. Bicout,et al. Isolation of yellow fever virus from nulliparous Haemagogus (Haemagogus) janthinomys in eastern Amazonia. , 2002, Vector borne and zoonotic diseases.
[392] V. K. Agadzi,et al. Recent yellow fever epidemics in Ghana (1969-1983). , 1986, East African medical journal.
[393] G. Chang,et al. Detection of yellow fever virus by polymerase chain reaction. , 1994, Clinical and diagnostic virology.
[394] M. Theiler,et al. Quantitative Studies of the Virus and Immune Serum Used in Vaccination against Yellow Fever 1 , 1935 .
[395] E. Snijders,et al. On the Protective Power of Yellow Fever Sera and Dengue Sera against Yellow Fever Virus. , 1934 .
[396] A. Barrett,et al. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. , 2006, Vaccine.
[397] D. McDermott,et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection , 2006, The Journal of experimental medicine.
[398] S. Toovey,et al. Travelers' knowledge, attitudes and practices on the prevention of infectious diseases: results from a study at Johannesburg International Airport. , 2004, Journal of travel medicine.
[399] Hugh H. Smith,et al. THE EFFECT OF PROLONGED CULTIVATION IN VITRO UPON THE PATHOGENICITY OF YELLOW FEVER VIRUS , 1937, The Journal of experimental medicine.
[400] M. Pavy,et al. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. , 2006, Antiviral research.
[401] C. Rice,et al. Heterogeneity in envelope protein sequence and N-linked glycosylation among yellow fever virus vaccine strains. , 1992, Virology.
[402] T. Monath,et al. The 1970 yellow fever epidemic in Okwoga District, Benue Plateau State, Nigeria. I. Epidemiological observations. , 1973, Bulletin of the World Health Organization.
[403] R. Patterson,et al. Drug allergy and protocols for management of drug allergies. , 1995, Allergy proceedings : the official journal of regional and state allergy societies.
[404] J. R. Brubaker,et al. T-helper cell epitopes on the E-glycoprotein of dengue 2 Jamaica virus. , 1994, Virology.
[405] C. Rice,et al. Yellow fever 17D as a vaccine vector for microbial CTL epitopes , 2005, The Journal of experimental medicine.
[406] S. Harrison,et al. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution , 1995, Nature.
[407] C. B. Cropp,et al. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. , 1981, The American journal of tropical medicine and hygiene.
[408] P. Meers,et al. Mass vaccination against yellow fever by scarification with 17D strain vaccine. , 1957, Annals of tropical medicine and parasitology.
[409] M. Myers,et al. Effect of interval between inoculation of live smallpox and yellow-fever vaccines on antigenicity in man. , 1972, The Journal of infectious diseases.
[410] P. F. Vasconcelos,et al. Hepatocyte lesions and cellular immune response in yellow fever infection. , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[411] S. G. Cohen,et al. Variations in egg white and egg yolk components of virus and rickettsial vaccines. , 1958, The Journal of allergy.
[412] T. Chambers,et al. Neuroadapted Yellow Fever Virus 17D: Determinants in the Envelope Protein Govern Neuroinvasiveness for SCID Mice , 2003, Journal of Virology.
[413] M. Theiler. SUSCEPTIBILITY OF WHITE MICE TO THE VIRUS OF YELLOW FEVER. , 1930, Science.
[414] V. Adhiyaman,et al. Effects of yellow fever vaccination , 2001, The Lancet.
[415] W. Bancroft,et al. Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients , 1981, Infection and immunity.
[416] R. Sidwell,et al. Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model. , 2007, Antiviral research.
[417] F. Guirakhoo,et al. Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing. , 2002, Vaccine.
[418] A. Barrett,et al. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. , 1986, The Journal of general virology.
[419] T. Monath,et al. Urban yellow fever epidemic in western Nigeria, 1987. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[420] T. Monath,et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. , 2002, The American journal of tropical medicine and hygiene.
[421] Max Theiler,et al. THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION , 1937, The Journal of experimental medicine.
[422] C. Smith,et al. Yellow fever vaccination in Malaya by subcutaneous injection and multiple puncture. Neutralizing antibody responses in persons with and without pre-existing antibody to related viruses. , 1962, Bulletin of the World Health Organization.
[423] W. Heneine,et al. Lack of evidence of endogenous avian leukosis virus and endogenous avian retrovirus transmission to measles, mumps, and rubella vaccine recipients. , 2001, Emerging infectious diseases.
[424] M. Katze,et al. The Host Response to West Nile Virus Infection Limits Viral Spread through the Activation of the Interferon Regulatory Factor 3 Pathway , 2004, Journal of Virology.
[425] K. Stiasny,et al. Characterization of monoclonal antibody-escape mutants of tick-borne encephalitis virus with reduced neuroinvasiveness in mice. , 1997, The Journal of general virology.
[426] R. Dal-Ré,et al. Interference assessment of yellow fever vaccine with the immune response to a single-dose inactivated hepatitis A vaccine (1440 EL.U.). A controlled study in adults. , 1996, Vaccine.
[427] A. Davidson,et al. Identification of a major determinant of mouse neurovirulence of dengue virus type 2 using stably cloned genomic-length cDNA. , 1998, The Journal of general virology.
[428] M. Cardosa,et al. Complement receptor mediates enhanced flavivirus replication in macrophages , 1983, The Journal of experimental medicine.
[429] Sudhir Gupta,et al. Severe T- and B-cell immune deficiency associated with malignant thymoma. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[430] M. Ng,et al. Possible involvement of receptors in the entry of Kunjin virus into Vero cells , 2005, Archives of Virology.
[431] R. Ferris,et al. Stabilized 17D strain yellow fever vaccine: dose response studies, clinical reactions and effects on hepatic function. , 1977, Journal of biological standardization.
[432] T. P. Hughes,et al. A Study of Inactivated Yellow Fever Virus As an Immunizing Agent , 1936, The Journal of Immunology.
[433] H. Guzmán,et al. Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. , 2001, The Journal of infectious diseases.
[434] M. Diallo,et al. Vertical transmission of the yellow fever virus by Aedes aegypti (Diptera, Culicidae): dynamics of infection in F1 adult progeny of orally infected females. , 2000, The American journal of tropical medicine and hygiene.
[435] T. Monath. Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans. , 1971, American journal of epidemiology.
[436] A. Barrett,et al. Comparative phylogenies of yellow fever isolates from Peru and Brazil. , 2003, FEMS immunology and medical microbiology.
[437] A. C. Gomes,et al. Entomological investigation of a sylvatic yellow fever area in São Paulo State, Brazil. , 2005, Cadernos de saude publica.
[438] M. Lhuillier,et al. Intérêt des IgM antiamariles dans le diagnostic et la surveillance épidémiologique de la fièvre jaune , 1983 .
[439] Ulrich Voigt,et al. [Neuritis of the optic nerve after vaccinations against hepatitis A, hepatitis B and yellow fever]. , 2001, Klinische Monatsblatter fur Augenheilkunde.
[440] R. Marchevsky,et al. Phenotypic analysis of yellow fever virus derived from complementary DNA. , 1995, The American journal of tropical medicine and hygiene.
[441] A. Rothman,et al. Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. , 1996, The Journal of clinical investigation.
[442] C. Rice,et al. Yellow Fever/Japanese Encephalitis Chimeric Viruses: Construction and Biological Properties , 1999, Journal of Virology.
[443] C. Struchiner,et al. Risk of fatal adverse events associated with 17DD yellow fever vaccine , 2004, Epidemiology and Infection.
[444] J. Kruppenbacher,et al. Immunogenicity of an inactivated hepatitis A vaccine administered according to two different schedules and the interference of other "travellers" vaccines with the immune response. , 1996, Vaccine.
[445] J. R. Brubaker,et al. T-helper cell and associated antibody response to synthetic peptides of the E glycoprotein of Murray Valley encephalitis virus , 1991, Journal of virology.
[446] A. Barrett,et al. Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes. , 1997, The Journal of general virology.
[447] C. Pannuti,et al. Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. , 1999, Vaccine.
[448] J. S. Porterfield. The haemagglutination-inhibition test in the diagnosis of yellow fever in man. , 1954, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[449] J. Schlesinger,et al. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. , 1985, Journal of immunology.
[450] P. Desprès,et al. Dendritic Cell-specific Intercellular Adhesion Molecule 3-grabbing Non-integrin (DC-SIGN)-mediated Enhancement of Dengue Virus Infection Is Independent of DC-SIGN Internalization Signals* , 2005, Journal of Biological Chemistry.
[451] A. Trejos,et al. Clinical pathology of yellow fever. , 1955, American journal of clinical pathology.
[452] A Marchler-Bauer,et al. Structural requirements for low-pH-induced rearrangements in the envelope glycoprotein of tick-borne encephalitis virus , 1996, Journal of virology.
[453] J. Schlesinger,et al. Cell surface expression of yellow fever virus non-structural glycoprotein NS1: consequences of interaction with antibody. , 1990, The Journal of general virology.
[454] A. Barrett,et al. Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine. , 1995, The Journal of general virology.
[455] R. B. Wallace,et al. Simultaneous administration of smallpox, measles, yellow fever, and diphtheria-pertussis-tetanus antigens to Nigerian children. , 1973, Bulletin of the World Health Organization.
[456] J. S. Porterfield. 2 – Antigenic Characteristics and Classification of Togaviridae , 1980 .
[457] B. Fritzell,et al. Combined vaccination against yellow fever and typhoid fever: a comparative trial. , 1994, Vaccine.
[458] J. Patz,et al. Global climate change and emerging infectious diseases. , 1996, JAMA.
[459] G. Boecken,et al. Jungle yellow fever in the central Amazon , 1996, The Lancet.
[460] V. Deubel,et al. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. , 2006, Virology.
[461] R. O. Spertzel,et al. Yellow Fever Vaccine: Direct Challenge of Monkeys Given Graded Doses of 17D Vaccine , 1973, Applied microbiology.
[462] R. Marchevsky,et al. Molecular and phenotypic analysis of a working seed lot of yellow fever virus 17DD vaccine strain produced from the secondary seed lot 102/84 with an additional passage in chicken embryos. , 2006, Biologicals : journal of the International Association of Biological Standardization.
[463] J. Lemasters,et al. Early midzonal cell death during low‐flow hypoxia in the isolated, perfused rat liver: Protection by allopurinol , 1988, Hepatology.
[464] E. Hindle. An experimental study of yellow fever , 1929 .
[465] P. Meers. Further observations on 17D-yellow fever vaccination by scarification, with and without simultaneous smallpox vaccination. , 1960, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[466] C. Wisseman,et al. Immunological studies with group B arthropod-borne viruses. I. Broadened neutralizing antibody spectrum induced by strain 17D yellow fever vaccine in human subjects previously infected with Japanese encephalitis virus. , 1962, The American journal of tropical medicine and hygiene.
[467] Ying Zhang,et al. Structures of immature flavivirus particles , 2003, The EMBO journal.
[468] Richard J. Kuhn,et al. Structure of the Flavivirus Helicase: Implications for Catalytic Activity, Protein Interactions, and Proteolytic Processing , 2005, Journal of Virology.
[469] J. Schlesinger,et al. Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b. , 1990, The Journal of general virology.
[470] C. Harinasuta,et al. The effect of interferon-alpha A on two cases of Japanese encephalitis in Thailand. , 1985, The Southeast Asian journal of tropical medicine and public health.
[471] H. Groot,et al. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. , 1962, Bulletin of the World Health Organization.
[472] C. Parrish,et al. Analysis of murine major histocompatibility complex class II-restricted T-cell responses to the flavivirus Kunjin by using vaccinia virus expression , 1992, Journal of virology.
[473] A. Ruiz-Linares,et al. The 15 amino acid residues preceding the amino terminus of the envelope protein in the yellow fever virus polyprotein precursor act as a signal peptide. , 1990, Virus research.
[474] C. B. Cropp,et al. Sensitive and specific monoclonal immunoassay for detecting yellow fever virus in laboratory and clinical specimens , 1986, Journal of clinical microbiology.
[475] N. Tauraso,et al. Quantitation of residual host protein in chicken embryo-derived vaccines by radial immunodiffusion. , 1971, Applied microbiology.
[476] Bimmi Shrestha,et al. Immune modulation by flaviviruses. , 2003, Advances in virus research.
[477] C. B. Cropp,et al. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1 , 1986, Journal of virology.
[478] H. Swartz. Systemic Allergic Reaction induced by Yellow Fever Vaccine. , 1943 .
[479] M. Guzmán,et al. Human Dengue Antibodies against Structural and Nonstructural Proteins , 2000, Clinical Diagnostic Laboratory Immunology.
[480] W. M. Shepherd,et al. A clinical study of stabilized 17D strain live attenuated yellow fever vaccine. , 1981, Journal of biological standardization.
[481] N. Shaffer,et al. Response to JE vaccine among HIV-infected children, Bangkok, Thailand. , 1998, The Southeast Asian journal of tropical medicine and public health.
[482] F. L. Soper. The 1957 Status of Yellow Fever in the Americas. , 1958 .
[483] S. Baron,et al. Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). , 1977, The Journal of infectious diseases.
[484] P. Young,et al. Production of dimer-specific and dengue virus group cross-reactive mouse monoclonal antibodies to the dengue 2 virus non-structural glycoprotein NS1. , 1991, The Journal of general virology.
[485] G. Blackburn,et al. The metabolic response to yellow fever immunization: protein-sparing modified fast. , 1981, The American journal of clinical nutrition.
[486] R. Lamb,et al. Virology: A class act , 2004, Nature.
[487] C. Rice,et al. Genetic Interaction of Flavivirus Nonstructural Proteins NS1 and NS4A as a Determinant of Replicase Function , 1999, Journal of Virology.
[488] R. Weiss. Adventitious viral genomes in vaccines but not in vaccinees. , 2001, Emerging infectious diseases.
[489] B. Falgout,et al. Derivation and Characterization of a Dengue Type 1 Host Range-Restricted Mutant Virus That Is Attenuated and Highly Immunogenic in Monkeys , 2002, Journal of Virology.
[490] A. Noga,et al. West Nile virus infection and serologic response among persons previously vaccinated against yellow fever and Japanese encephalitis viruses. , 2005, Vector borne and zoonotic diseases.
[491] A. Barrett,et al. Genetic variation in yellow fever virus: duplication in the 3' noncoding region of strains from Africa. , 1996, Virology.
[492] A. Barrett,et al. Examination of the immunological relationships between flaviviruses using yellow fever virus monoclonal antibodies. , 1985, The Journal of general virology.
[493] Cheryl H. Dean,et al. Cutaneous Delivery of a Live, Attenuated Chimeric Flavivirus Vaccines against Japanese Encephalitis (ChimeriVaxTM-JE) in Non-Human Primates , 2005, Human vaccines.
[494] H. Zeller,et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. , 2004, The Journal of infectious diseases.
[495] A. Barrett,et al. Comparison of neurovirulence of different strains of yellow fever virus in mice. , 1986, The Journal of general virology.
[496] T. Monath,et al. Antiviral (RNA) activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related substances. , 1992, Journal of natural products.
[497] Cost-effectiveness of immunization in The Gambia. , 1985, The Journal of tropical medicine and hygiene.
[498] J. Dalrymple,et al. Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys. , 1990, Antiviral research.
[499] F. Ennis,et al. Dengue virus-specific, human CD4+ CD8- cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones , 1991, Journal of virology.
[500] Peter F. Stadler,et al. Spontaneous and Engineered Deletions in the 3′ Noncoding Region of Tick-Borne Encephalitis Virus: Construction of Highly Attenuated Mutants of a Flavivirus , 1998, Journal of Virology.
[501] A. Barrett,et al. Size Heterogeneity in the 3′ Noncoding Region of South American Isolates of Yellow Fever Virus , 2005, Journal of Virology.
[502] J. Schlesinger,et al. Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. , 1995, The Journal of general virology.
[503] H. Zeller,et al. Shortage of vaccines during a yellow fever outbreak in Guinea , 2001, The Lancet.
[504] J. Mascola,et al. Human skin Langerhans cells are targets of dengue virus infection , 2000, Nature Medicine.
[505] T. Jones. A chimeric live attenuated vaccine against Japanese encephalitis , 2004, Expert review of vaccines.
[506] A. Allison,et al. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection , 1977, The Journal of experimental medicine.
[507] R. Garratt,et al. Expression of foreign protein epitopes at the surface of recombinant yellow fever 17D viruses based on three-dimensional modeling of its envelope protein , 2007, Cell Biochemistry and Biophysics.
[508] A. Barrett,et al. Comparison of the nucleotide and deduced amino acid sequences of the structural protein genes of the yellow fever 17DD vaccine strain from Senegal with those of other yellow fever vaccine viruses. , 1993, Vaccine.
[509] E. Hayes,et al. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004. , 2006, The American journal of tropical medicine and hygiene.
[510] H. B. Sprague,et al. Egg Allergy ; Significance in Typhus and Yellow Fever Immunization. , 1945 .
[511] J. Schlesinger,et al. Homogeneity among Senegalese strains of yellow fever virus. , 1985, The American journal of tropical medicine and hygiene.
[512] S. D. Nishioka,et al. Overdose of yellow fever vaccine: a preventable error? , 2002, Revista da Sociedade Brasileira de Medicina Tropical.
[513] L. Dalgarno,et al. Neurovirulence and neuroinvasiveness of Murray Valley encephalitis virus mutants selected by passage in a monkey kidney cell line. , 1995, The Journal of general virology.
[514] P. Anderson,et al. Cell Proteins TIA-1 and TIAR Interact with the 3′ Stem-Loop of the West Nile Virus Complementary Minus-Strand RNA and Facilitate Virus Replication , 2002, Journal of Virology.
[515] B. Miller,et al. Epidemic yellow fever caused by an incompetent mosquito vector. , 1989, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit (GTZ).
[516] J. Schlesinger,et al. Comparative immunochemical and biological analysis of African and South American yellow fever viruses , 2005, Archives of Virology.
[517] T. Monath,et al. Yellow fever: Victor, Victoria? Conqueror, conquest? Epidemics and research in the last forty years and prospects for the future. , 1991, The American journal of tropical medicine and hygiene.
[518] P. Hantson,et al. A Belgian traveler who acquired yellow fever in the Gambia. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[519] F. Guirakhoo,et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. , 2003, The Journal of infectious diseases.
[520] B. Fritzell,et al. Study of combined vaccination against yellow fever and measles in infants from six to nine months. , 1989, Journal of Biological Standardization.
[521] A. Barrett,et al. Identification of monoclonal antibodies that distinguish between 17D-204 and other strains of yellow fever virus. , 1990, The Journal of general virology.
[522] Y. Modis,et al. Structure of the dengue virus envelope protein after membrane fusion , 2004, Nature.
[523] Denise A. Martin,et al. Immunoassay Targeting Nonstructural Protein 5 To Differentiate West Nile Virus Infection from Dengue and St. Louis Encephalitis Virus Infections and from Flavivirus Vaccination , 2003, Journal of Clinical Microbiology.
[524] M. Lhuillier,et al. Epidémie rurale de fièvre jaune avec transmission interhumaine en Côte d'Ivoire en 1982. , 1985 .
[525] T. Monath,et al. Lymphocytic 2',5'-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine , 1995, Clinical and diagnostic laboratory immunology.
[526] B. Mondet. [Yellow fever epidemiology in Brazil]. , 2001, Bulletin de la Societe de pathologie exotique.
[527] B. Yvonnet,et al. Simultaneous administration of hepatitis B and yellow fever vaccines , 1986, Journal of medical virology.
[528] R. Shope,et al. Aedes aegypti strain fitness for yellow fever virus transmission. , 1977, The American journal of tropical medicine and hygiene.
[529] F. L. Soper. Yellow Fever: the Present Situation (October, 1938} with Special Reference to South America. , 1938 .
[530] R. Marchevsky,et al. Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblasts: yields, thermo and genetic stability, attenuation and immunogenicity. , 2005, Vaccine.
[531] F. Macnamara. Reactions following neurotropic yellow fever vaccine given by scarification in Nigeria. , 1953, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[532] J. Schlesinger,et al. Analysis of 17D yellow fever virus envelope protein epitopes using monoclonal antibodies. , 1984, The Journal of general virology.
[533] Robert Anderson,et al. PrM- and Cell-Binding Domains of the Dengue Virus E Protein , 1999, Journal of Virology.
[534] A Hay. Simulants, stimulants and diseases: the evolution of the United States biological warfare programme, 1945-60. , 1999, Medicine, conflict, and survival.
[535] Luiz Antonio Bastos Camacho,et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. , 2004, Revista de saude publica.
[536] T. Monath. Yellow fever: a medically neglected disease. Report on a seminar. , 1987, Reviews of infectious diseases.
[537] Wheelock Ef,et al. CIRCULATING VIRUS, INTERFERON AND ANTIBODY AFTER VACCINATION WITH THE 17-D STRAIN OF YELLOW-FEVER VIRUS. , 1965 .
[538] F. Guirakhoo,et al. Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All , 2006, Human vaccines.
[539] W. Bancroft,et al. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. , 1984, The Journal of infectious diseases.
[540] C. Rice,et al. A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. , 2003, The Journal of general virology.
[541] A. Drouet,et al. [Meningoencephalitis after vaccination against yellow fever with the 17 D strain: 2 cases]. , 1993, La Revue de medecine interne.
[542] A. Filipe,et al. Laboratory infection with Zika virus after vaccination against yellow fever , 1973, Archiv für die gesamte Virusforschung.
[543] J. H. Strauss,et al. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. , 1985, Science.
[544] L. Haas. Encephalitis after Yellow Fever Vaccination , 1954 .
[545] N. Scrimshaw,et al. Infection and nutritional status. II. Effect of mild virus infection induced by 17-D yellow fever vaccine on nitrogen metabolism in children. , 1961, The American journal of clinical nutrition.
[546] T. Monath,et al. The effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinations. , 1984, Bulletin of the World Health Organization.
[547] E. Gould,et al. Antigenic analysis of yellow fever virus glycoproteins: use of monoclonal antibodies in enzyme-linked immunosorbent assays. , 1986, Journal of virological methods.
[548] M. Eaton,et al. JAUNDICE IN ARMY PERSONNEL IN THE WESTERN REGION OF THE UNITED STATES AND ITS RELATION TO VACCINATION AGAINST YELLOW FEVERPART I , 1944 .
[549] M. Cetron,et al. Yellow Fever Vaccine-Associated Disease , 2004 .
[550] M. Tao,et al. Protective Mechanisms Induced by a Japanese Encephalitis Virus DNA Vaccine: Requirement for Antibody but Not CD8+Cytotoxic T-Cell Responses , 2001, Journal of Virology.
[551] P. F. Vasconcelos,et al. Midzonal lesions in yellow fever: a specific pattern of liver injury caused by direct virus action and in situ inflammatory response. , 2006, Medical hypotheses.
[552] F. Guirakhoo,et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. , 2002, Vaccine.
[553] J. D. White,et al. ELECTRON MICROSCOPIC AND IMMUNOFLUORESCENT OBSERVATIONS ON MONKEY LIVER AND TISSUE CULTURE CELLS INFECTED WITH THE ASIBI STRAIN OF YELLOW FEVER VIRUS. , 1964, The American journal of pathology.
[554] J. H. Strauss,et al. Chimeric Yellow Fever/Dengue Virus as a Candidate Dengue Vaccine: Quantitation of the Dengue Virus-Specific CD8 T-Cell Response , 2000, Journal of Virology.
[555] C. Rice,et al. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes , 2005, The Journal of experimental medicine.
[556] R. Tesh,et al. Effect of human gamma interferon on yellow fever virus infection. , 1988, The American journal of tropical medicine and hygiene.
[557] T. Monath,et al. ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy , 2004, Journal of Virology.
[558] J. Oudart,et al. [Proteinuria, proteinaemia, and serum transaminase activity in 23 confirmed cases of yellow fever]. , 1970, Bulletin of the World Health Organization.
[559] L. N. Payne,et al. Contaminant viruses in two live virus vaccines produced in chick cells , 1966, Journal of Hygiene.
[560] C. Okell. Experiments with yellow fever vaccine in monkeys , 1930 .
[561] G. Cook. Fatal yellow fever contracted at the Hospital for Tropical Diseases, London, UK, in 1930. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[562] S. Rodrigues,et al. Epidemic of jungle yellow fever in Brazil, 2000: Implications of climatic alterations in disease spread , 2001, Journal of medical virology.
[563] E. Gould,et al. Neutralization of yellow fever virus studied using monoclonal and polyclonal antibodies. , 1985, The Journal of general virology.
[564] J. Fox,et al. ENCEPHALITIS IN MAN FOLLOWING VACCINATION WITH 17 D YELLOW FEVER VIRUS , 1942 .
[565] D. Annane,et al. Corticosteroids for treating severe sepsis and septic shock. , 2004, The Cochrane database of systematic reviews.
[566] H. Hanson. Observations on the Age and Sex Incidence of Deaths and Recoveries in the Yellow Fever Epidemic in the Department of Lambayeque, Peru, in 1921 , 1929 .